Effect of carvedilol in preventing heart failure following herceptin therapy

assessment of prophylactic treatment with carvedilol in incidence of heart failure in patients with HER2 positive breast cancer receiving trastuzumab

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT2014112019840N1

Enrollment

100

Registered

2015-02-21

Start date

2014-09-01

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

breast cancer. Malignant neoplasm of breast

Interventions

Intervention 1: Intervention:Tab Carvedilol 6.25-12.5 mg bid for 3 months or up to the time when symptoms of heart failure develop. Intervention 2: Control:placebo with the same dose and duration of c

Treatment - Drugs

Placebo

Intervention:Tab Carvedilol 6.25-12.5 mg bid for 3 months or up to the time when symptoms of heart failure develop

Control:placebo with the same dose and duration of carvedilol therapy

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: Inclusion:patients with HER2 positive breast cancer who are candidate for herceptin therapy Exclusion: history of systolic heart failure (EF<50), history of anthracycline therapy,contraindications for beta blockers, history of coronary artery disease,symptoms of heart failure including orthopnea or PND or dyspnea on exertion

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Heart failure. Timepoint: 3 months after administration of herceptin. Method of measurement: echocardiography.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAlborz Sherafati

Imam Khomeini hospital

asherafati@student.tums.ac.ir+98 21 6693 9537

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026